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grafting for unprotected left main coronary artery
disease: a meta-analysis of four randomized trials
and seventeen observational studies
Qing Li1, Zhi Zhang2 and Rui-Xing Yin1*Abstract
Background: The clinical application of drug-eluting stents (DES) or coronary artery bypass grafting (CABG) for
unprotected left main coronary artery disease (ULMCAD) is still controversial. The purpose of this meta-analysis was
to compare the safety and efficacy between DES and CABG for ULMCAD.
Methods: Databases of MEDLINE, EMBASE and the Cochrane Library were systematically searched.
Results: Twenty-one studies with 8,413 patients were included in this meta-analysis. The risk was lower in DES than
in CABG groups at the early outcomes of death (risk ratio (RR): 0.49, 95% confidence interval (CI): 0.30–0.78),
cerebrovascular events (RR: 0.19, 95% CI: 0.08–0.45) and composite endpoint (RR: 0.53, 95% CI: 0.40–0.70); death
after 2 years (RR: 0.81, 95% CI: 0.66–0.99), 4 years (RR: 0.69, 95% CI: 0.53–0.90), 5 years (OR: 0.76, 95% CI: 0.61–0.95)
and their total effect (RR: 0.79, 95% CI: 0.71–0.87); composite endpoint 1 year (RR: 0.69, 95% CI: 0.58–0.83), 4 years
(RR: 0.69, 95% CI: 0.53–0.88), 5 years (RR: 0.74, 95% CI: 0.59–0.92) and their total effect (RR: 0.78, 95% CI: 0.71–0.85).
There were no significant differences in the risk for the early outcomes of myocardial infarction (RR: 0.97, 95% CI:
0.68–1.38), death 1 year (OR: 0.81, 95% CI: 0.57–1.15) and 3 years (OR: 0.85, 95% CI: 0.69–1.04), composite endpoint
of 2 years (RR: 0.88, 95% CI: 0.72–1.09) and 3 years (RR: 0.87, 95% CI: 0.73–1.04). Nonetheless, there was a lower risk
for revascularization associated with CABG from 1 to 5 years and their total effect (RR: 3.77, 95% CI: 3.35–4.26). There
was no difference in death, myocardial infarction, cerebrovascular events or revascularization at 1 year between RCT
and observational groups.
Conclusions: Our meta-analysis indicates that DES has higher safety but higher revascularization than CABG in
patients with ULMCAD in the 5 years after intervention.
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Safety and efficacy, Meta-analysisBackground
As is well known, approximately 4 to 9% of patients
undergoing diagnostic coronary angiography [1] are found
to have unprotected left main stenosis which has been
shown to portend high mortality [2,3]. Percutaneous
coronary intervention (PCI) involving drug-eluting stents* Correspondence: yinruixing@163.com
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reproduction in any medium, provided the or(DES) have increasingly been used to treat unprotected
left main coronary artery disease (ULMCAD) in recent
years, although coronary artery bypass grafting (CABG)
has been the treatment of choice historically [4,5]. One
of the main limitations of PCI for ULMCAD is in-stent
restenosis and the need for repeat revascularization,
especially in bare-metal stents [6,7]; therefore, the European
Society of Cardiology guidelines and American Heart
Association guidelines suggest that PCI for ULMCAD
should be only reserved for those who are poor candidates
for CABG [8]. However, several meta-analyses [9-12] ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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results are controversial, and many new clinical trials
have been published in recent years [13-16]. Therefore,
it is necessary to conduct a new meta-analysis and to assess
the safety and efficacy of DES and CABG among patients
with ULMCAD in the early outcomes (≤30 days or
in-hospital) and 1 to 5 years follow-up, and it is also
necessary to compare the difference in safety and efficacy




The data of this meta-analysis were obtained from the
following sources: MEDLINE via PubMed (from 1950 to
June 2012), EMBASE (June 1980 to June 2012) and the
Cochrane Library database (Cochrane Central Register of
Controlled Trials, from 1991 to June 2012). The following
keywords were used: “coronary artery bypass”, “drug-eluting
stent”, “paclitaxel-eluting stent”, “sirolimus-eluting stent”,
and “left main coronary artery”. The above search strategy
described was used to obtain titles and abstracts of studies
that may have been relevant to this review. The titles
and abstracts were screened independently by two authors
(Q Li and Z Zhang), who discarded studies that were not
applicable. When multiple reports from the same patients
were found, only the study with the most complete data
set was included in the meta-analysis. However, duplicate
patients of different articles that have different types of data
of outcomes were included both. Any disagreements were
arbitrated by discussion with a third reviewer (RX Yin).
Included and excluded studies
Studies were included in this meta-analysis if they
met the following criteria: 1) clinical trials published
in peer-reviewed journals with full available text in English;
2) clinical trials comparing CABG with DES for LMCAD;
3) reporting at least one relevant clinical endpoint including
revascularization, myocardial infarction, cerebrovascular
events, death or the composite endpoint (death, myocardial
infarction, or cerebrovascular events); and 4) follow-up
duration ≥30 days. Excluded studies: 1) studies using only
bare-metal stents or mixtures of bare-metal stents and
DES but not comparing DES with CABG separately in
the PCI group were excluded from this study; 2) studies
in which it was not possible to extract data from the
published results as well as those studies that did not
report appropriate outcomes were also excluded.
Types of outcome measures
The safety endpoints of this meta-analysis were death,
cerebrovascular events, myocardial infarction and the
composite endpoint of death, myocardial infarction
or cerebrovascular events. The efficacy endpoint wasrevascularization. Death was defined as death from
any cause. Myocardial infarction included Q-wave and
non-Q-wave myocardial infarction. Cerebrovascular events
included ischemic attacks, stroke and reversible ischemic
neurological deficits. Revascularization was the need for
repeated CABG or PCI.
Data extraction and management
Two investigators independently extracted data according
to the author details and the following information was
extracted from each study: methodological quality, first
author, the year of publication, number of patients in
each group (CABG or DES), baseline characteristics,
interventions, outcomes, and duration of follow-up.
Otherwise, probabilities of death or other endpoints
were estimated from published Kaplan-Meier survival
curves. Discrepancies were resolved by discussion. When
repeated publications of the same trial were identified,
data were extracted from the repeated publications and
reported as a single trial.
Quality of the evidence recommendations methodology
The evidence recommendations in our meta-analysis were
graded according to the Grading of Recommendations
Assessment Development and Evaluation (GRADE)
system by Grade software [17]. The quality of the evidence
was classified in four levels: high (⊕⊕⊕⊕), moderate
(⊕⊕⊕⊝), low (⊕⊕⊝⊝) or very low (⊕⊝⊝⊝).
Statistical analysis
We carried out statistical analysis by the Review Manager
software 5.1.0 (updated in March 2011 by the Cochrane
Collaboration). Dichotomous outcomes of individual studies
were expressed as risk ratio (RR) with 95% confidence
intervals (CI). The pooled effects were calculated using
fixed-effects models when there was no significant
heterogeneity but the random effects model was analyzed
to ensure robustness of the model chosen and susceptibility
to outliers, or using random effects models when there
was significant heterogeneity. The fixed effects model was
analyzed to ensure robustness of the model chosen and
susceptibility to outliers. The point estimate of the RR was
considered statistically significant at the 2-tailed P ≤0.05
level. Heterogeneity was analyzed using a χ2 test on N-1
degrees of freedom [18]. I2 values of 25%, 50% and 75%
correspond to low, medium and high levels of heterogeneity,
respectively. Subgroup analysis was used to explore possible
sources of heterogeneity (e.g., duration of follow-up, type
of outcomes and study quality). Sensitivity analyses were
performed omitting a single study at a time or analyzing
another model chosen. If enough studies were identified,
funnel plots were used to investigate reporting biases [19].
The baseline characteristics were analyzed with χ2 test for
categorical variables.
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Characteristics of included studies
Twenty-one studies met our criteria for inclusion in the
meta-analysis (Figure 1). Four studies were randomized
controlled trials [13,15,20,21] and seventeen studies were
observational studies [4-8,14,16,22-36]. Several studies
may have had duplicate patients but they had different
types data of outcomes, e.g., one study [20] included
death outcomes but another [13] did not. A total of
8,413 patients were included in the analysis. There were
4,731 patients who received CABG and 3,682 patients
who received PCI with DES. The main characteristics of
the studies are shown in Table 1.
Baseline characteristics of the trials
The baseline clinical characteristics between the PCI and
CABG groups are detailed in Table 2. There were no
significant differences in the prevalence of hypertension,
current smoking, diabetes mellitus, previous stroke, and
chronic renal failure between the two groups (P >0.05
for all). The proportions of females and previous PCI
were lower but the prevalence of hyperlipidemia, previous
myocardial infarction and right coronary artery disease
were higher in CABG than in PCI groups (P <0.05 for all).
Clinical outcomes
The early outcomes (≤30 days or in-hospital)
The early outcomes of DES and CABG groups and
the pooled effects are shown in Figure 2. Pooled effects
indicated that CABG group had higher risk of death (RR:
0.49, 95% CI: 0.30–0.78, P = 0.003), cerebrovascular events
(RR: 0.19, 95% CI: 0.08–0.45, P = 0.0002) and composite
endpoint (RR: 0.53, 95% CI: 0.40–0.70, P <0.00001) than
the PCI group. There was no difference in myocardial
infarction (RR: 0.97, 95% CI: 0.68–1.38, P = 0.86) between
CABG and PCI groups.Figure 1 Flow chart showing study selection process.Death after 1 to 5 years post-operation
Death after 1 to 5 years post-operation between the
CABG and PCI groups is shown in Figure 3. Pooled
effects showed that CABG group had higher risk of
death than the PCI group after 2 years (RR: 0.81, 95% CI:
0.66–0.99, P = 0.04), 4 years (RR: 0.69, 95% CI: 0.53–0.90,
P = 0.007), 5 years (OR: 0.76, 95% CI: 0.61–0.95, P = 0.02)
and total pooled outcome (RR: 0.79, 95% CI: 0.71–0.87,
P <0.00001). There was no difference in deaths at 1 year
(RR: 0.80, 95% CI: 0.63–1.02, P = 0.07) and 3 years (OR:
0.85, 95% CI: 0.69–1.04, P = 0.11) between the CABG
and PCI groups.Composite endpoint at 1 to 5 years post-operation
The outcomes of composite endpoint of death, myocardial
infarction and cerebrovascular events at 1 to 5 year post-
operation between CABG and PCI groups are detailed in
Figure 4. Pooled effects showed that CABG group had
higher composite endpoint risk than PCI group after 1
year (RR: 0.69, 95% CI: 0.58–0.83, P = 0.0001), 4 years
(RR: 0.69, 95% CI: 0.53–0.88, P = 0.003), 5 years (RR: 0.74,
95% CI: 0.59–0.92, P = 0.007) and total pooled outcome
(RR: 0.78, 95% CI: 0.71–0.85, P <0.00001). There was no
difference in composite endpoint at 2 years (RR: 0.88, 95%
CI: 0.72–1.09, P = 0.24) and 3 years (RR: 0.87, 95% CI:
0.73–1.04, P = 0.14) between the CABG and PCI groups.Revascularization at 1 to 5 years post-operation
The outcomes of revascularization at 1 to 5 years post-
operation between PCI and CABG groups are shown in
Figure 5. Pooled effects showed that PCI group had
higher revascularization risk than CABG group at 1 year
(RR:3.38, 95% CI: 2.75–4.15, P <0.00001), 2 years (RR:
3.81, 95% CI: 2.93–4.95, P <0.00001), 3 years (RR: 4.42,
95% CI: 3.40–5.75, P <0.00001), 4 years (RR: 3.22, 95%
CI: 2.28–4.54, P <0.00001) and 5 years (RR: 4.43, 95%
CI: 3.08–6.37, P <0.00001), and total pooled outcome
(RR: 3.77, 95% CI: 3.35–4.26, P <0.00001).Outcomes at 1 year between RCT and observational groups
The outcomes of RCT and observational groups at 1
year are shown in Figures 6, 7, 8, 9. Pooled effects
showed that there were no different outcomes between
RCT and observational groups in death, myocardial
infarction, cerebrovascular events or revascularization.
There were also no differences in both death and
myocardial infarction for CABG and PCI in both
RCT and observational groups (P >0.05 for each). The
PCI group had higher revascularization risk than the
CABG group (P <0.00001), whereas the CABG group had
higher cerebrovascular events risk than the PCI group
(P = 0.001) in the two groups.
Table 1 Main characteristics of included studies
Study Year Patients
(DES/CABG)




Lee et al. [27] 2006 50/123 2003–2006 Observational 70/72 death, MI, TVR, stroke 1
Chieffo et al. [24] 2006 107/142 2002–2004 Observational 68/64 death, MI, TVR, stroke, MACCE 1
Palmerini et al. [29] 2007 98/161 2003–2006 Observational 78/81 death, MI, TVR 2
Sanmartin et al. [32] 2007 96/245 2000–2005 Observational 66/66 death, MI, TVR, stroke, MACCE 1
Makikallio et al. [28] 2008 49/238 2005–2007 Observational 72/70 death, MI, TVR, stroke, MACCE 1
White et al. [35] 2008 67/67 2003–2007 Observational 72/68 death, MACCE 2
Seung et al. [33] 2008 396/396 2003–2006 Observational 66/66 death, TVR, MACCE 3
Boudriot et al. [20] 2008 79/80 2003–2007 RCT 69/66 death, MI, TVR, MACCE 1
Cheng et al. [22] 2009 94/216 2000–2007 Observational 67/68 death, TVR, MACCE 3
Ghenim et al. [25] 2009 105/106 2004–2007 Observational 80/79 TVR, MACCE 1
Morice et al. [21] 2010 357/348 2005–2007 RCT 66/65 death, MI, TVR, stroke 1
Chieffo et al. [23] 2010 107/142 2002–2004 Observational 63/67 death, MI, TVR, stroke, MACCE 5
Kang et al. [26] 2010 205/257 2003–2006 Observational 64/65 death, MI, TVR, stroke, MACCE 3
Park et al. [31] 2010 784/690 2003–2006 Observational 63/64 death, TVR, MACCE 5
Park et al. [30] 2010 176/219 2003–2004 Observational 61/62 death, TVR, MI, stroke 5
Shimizu et al. [34] 2010 64/89 2004–2007 Observational 71/70 MI, TVR, stroke 1
Wu et al. [36] 2010 131/245 2003–2006 Observational 62/64 death, TVR, MACCE 4
Boudriot et al. [13] 2011 100/101 2003–2009 RCT 66/69 death, MI, TVR, MACCE 1
Park et al. [15] 2011 300/300 2004–2009 RCT 61/62 death, MI, TVR, stroke 2
Caggegi et al. [14] 2011 222/361 2002–2010 Observational 67/66 death, MI, TVR 1
Rittger et al. [16] 2011 95/205 2004–2007 Observational 71/68 death, stroke, TVR 2
MACCE: Major adverse cardiac cerebrovascular events; MI: Myocardial infarction; TVR: Target vessel revascularization.
Li et al. Trials 2013, 14:133 Page 4 of 13
http://www.trialsjournal.com/content/14/1/133Sensitivity analysis
Sensitivity analyses were performed to assess the contribu-
tion of each study to the pooled estimate and by excluding
individual studies one at a time and recalculating the
pooled RR estimates for the remaining studies. Eliminating





Current smoking/Sample size 893/276
Hyperlipidemia/Sample size 1341/28
Diabetes mellitus/Sample size 959/285
Previous myocardial infarction/Sample size 320/253
Previous stroke/Sample size 204/188
Previous PCI/Sample size 415/202
CRF/Sample size 156/261
RCA/Sample size 1009/19
Comparison of preoperative variable in DES and CABG patients. All variables come
renal failure.100 patients in each group did not substantially change
the pooled point estimate. Moreover, analysis of four
RCTs separately did not also substantively alter the overall
result of our analysis. Last but not least, performing
transition of model also did not substantially change the












from the individual studies included. RCA: Right coronary artery; CRF: Chronic
Figure 2 Comparison of the early outcomes (≤30 days or in-hospital) between PCI and CABG groups.
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The results of the present meta-analysis showed that the
early subtotal outcomes of death, cerebrovascular events
and composite endpoint; death at 2, 4 and 5 years post-
operation and composite endpoint at 1, 4 and 5 years
post-operation, combined with their total outcomes,
were lower risk in PCI than in CABG groups. There was nodifference in the risk for the early outcomes of myocardial
infarction, death at 3 years and composite endpoint at
2 and 3 years. Nevertheless, there was a lower risk for
revascularization associated with CABG. There was no
significant difference in death, myocardial infarction,
cerebrovascular events or revascularization between RCT
and observational groups.
Figure 3 Comparison of the outcome of death from 1 to 5 years post-operation between PCI and CABG groups.
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and observational studies, showed no significant differences
in the safety between CABG and DES, and superiority of
CABG to DES for repeated revascularization in patients
with ULMCAD. A meta-analysis including 3,773 patients
and follow-up of 3 years believed that PCI was emerging
as an acceptable option. However, the PCI group in the
meta-analysis was mixed with bare-metal stents and DES
but did not compare DES with CABG separately, whichmight have led to the less robust results [37]. The
meta-analysis by Lee et al. [10] included 8 clinical studies
and 1 year follow-up. However, the number of patients in
the CABG and DES groups was wrong in one study [38]
and the total number of studies and patients was small,
which may also have led to weak results. The meta-analysis
by Zheng et al. [12] published in 2011 was heavily based
on observational studies (13 observational studies and 2
RCTs) and a 5-year follow-up in the two groups, however,
Figure 4 Comparison of the outcome of composite endpoint of death, myocardial infarction and cerebrovascular events from 1 to 5
years post-operation between PCI and CABG groups.
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only from randomized trials but also from observational
studies, which did not strengthen the conclusion.
Two recent meta-analyses including a single RCT have
been published. In one meta-analysis including three RCTs,
Kajimoto et al. [9] showed that there was no significantdifference in the risk of death and myocardial infarction
in two groups but was superior to target vessel revascular-
ization and major adverse cardiac and cerebrovascular
events in CABG than in PCI group at 1 year. Therefore,
they believed that CABG remains the standard of care for
the treatment of left main coronary artery disease.
Figure 5 Comparison of the revascularization at 1 to 5 years post-operation between PCI and CABG groups.
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[39] with 1,800 patients mixed with left main coronary
artery disease and three-vessel coronary disease but not
comparing the results of left main coronary artery disease
in the two groups separately, which also affected the
results.
The meta-analysis by Desch et al. [40] including four
RCTs showed that there were no significant differences in
the clinical endpoints of death and myocardial infarctionbetween the PCI and CABG groups. While stroke was
more frequent in surgical patients, the risk of repeated
revascularization was higher in the PCI up to 2 years.
Therefore they believe PCI to be useful only as an alterna-
tive to CABG in anatomically suited patients and with an
increased risk of adverse surgical outcomes. However, the
meta-analysis included an article [41] assessing mixed bare-
metal stents and DES but not comparing DES with CABG
separately, and the size of the study population was small.
Figure 6 Comparison of DES and CABG of myocardial infarction at 1 year post-operation between RCT and observational groups.
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that mixed left main coronary artery disease and
three-vessel coronary disease but did not compare
left main coronary artery disease in the two groups
separately, or articles assessing mixed bare-metal
stents and DES but not comparing DES with CABG sep-
arately, and we included more studies (four RCTs and 17
observational studies) and larger number of patientsFigure 7 Comparison of DES and CABG for the outcome of cerebrova
observational groups.(total 8,413). Further, we performed the systematic review
using a different method, which may be the reason for the
different outcomes with the previous meta-analyses. We
also performed the analysis of RCT and observational
groups separately, there was no significant difference in
death, myocardial infarction, cerebrovascular events or
revascularization between RCT and observational groups.
These also made our conclusion more robust.scular events at 1 year post-operation between RCT and
Figure 8 Comparison of DES and CABG for the outcome of death at 1 year post-operation between RCT and observational groups.
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Some of the evidence GRADE level was low because most
of the included studies were poor quality. Seventeen studies
were observational studies and were not performed with
the method of randomization and allocation concealment,Figure 9 Comparison of DES and CABG for the outcome of revascular
observational groups.which might lead to selection bias and an exaggerated RR.
Combined with not performing methods of blinding could
result in performance, attrition and detection bias. These
method limitations caused down grade of the quality of
evidence. On the other hand, some differences in baselineization at 1 year post-operation between RCT and
Figure 10 Summary of finding for the main comparison.
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unknown influence on the estimated effects that would
increase inconsistent results, and some trials in these
groups had inconsistent results and high heterogeneity; all
this also caused downgrade of the quality of evidence.
Furthermore, only the articles in English were included in
this analysis and we were unable to search for grey articles,
which might be a source of potential publication bias in
this study. The low quality of GRADE did not allow a
robust conclusion for some groups in this population.
However, some total or subtotal RRs had a large effect.
All RCTs describe the method of randomization and
allocation concealment. These subgroups of RCT had
consistent results and low heterogeneity, but the size of
the study population of RCT was a bit small and the
pooled analysis showed a wide CI. Therefore, some of
the evidence GRADE level was moderate (Figure 10).
Other limitations should also be discussed in our
study. Firstly, only four RCT were in the included studies
in our meta-analysis, and two RCTs had duplicate patients
and most types of data of outcomes in the two studies
were repeated. Therefore, in the future, more randomized
studies to compare DES with CABG in patients with left
main coronary artery disease are necessary. What is more,
many studies’ period of follow-up was short and only
three observational studies [23,30,31] reported long-term
follow-up (5 years). Therefore, more long-term results are
necessary in the future.Conclusions
Our meta-analysis indicates that DES has a lower safety
risk than CABG but is inferior to CABG for repeated
revascularization in patients with ULMCAD in the 5 years
after intervention. There was no difference in death,
myocardial infarction, cerebrovascular events or revascu-
larization between RCT and observational groups.
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